Sept. 13 Clinical Quick Takes: Amgen, Atara, MS biomarkers and switching in psoriasis

Clinical holds on two Amgen trials for cardiac safety signal
Amgen (NASDAQ:AMGN) said FDA placed a clinical hold on a Phase I trial of MCL1 inhibitor AMG 397 “to evaluate a safety signal for cardiac toxicity.” Amgen voluntarily

Read the full 385 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE